VolitionRx initiated with a Buy at JonesResearch

JonesResearch analyst Justin Walsh initiated coverage of VolitionRx (VNRX) with a Buy rating and $3 price target VolitionRx is a commercial-stage epigenetics company leveraging nucleosomes and transcription factors to diagnose and monitor human and animal health, the analyst tells investors in a research note. The firm believes the company’s strategy to drive widespread adoption of its patent-protected portfolio of Nu.Q assays via collaborations with major marketing partners in the human and animal health spaces is achievable and could drive “highly favorable” operating margins.